Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity

por Villarreal, Daniel O., Chin, Diana, Smith, Melissa A., Luistro, Leopoldo L., Snyder, Linda A.
Publicado 2017

Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment

por Villarreal, Daniel O., Allegrezza, Michael J., Smith, Melissa A., Chin, Diana, Luistro, Leopoldo L., Snyder, Linda A.
Publicado 2017

Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment

por Nair-Gupta, Priyanka, Rudnick, Stephen I., Luistro, Leopoldo, Smith, Melissa, McDaid, Ronan, Li, Yingzhe, Pillarisetti, Kodandaram, Joseph, Jocelin, Heidrich, Bradley, Packman, Kathryn, Attar, Ricardo, Gaudet, François
Publicado 2020

A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3

por Zwolak, Adam, Chan, Szeman Ruby, Harvilla, Paul, Mahady, Sally, Armstrong, Anthony A., Luistro, Leopoldo, Tamot, Ninkka, Yamada, Douglas, Derebe, Mehabaw, Pomerantz, Steven, Chiu, Mark, Ganesan, Rajkumar, Chowdhury, Partha
Publicado 2022